Compare Merck & Co., Inc. (MRK) vs Block Inc (XYZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Block Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while Block Inc trades at $79.35 (market cap $48.12B). The key difference: Merck & Co., Inc. is far larger — about 7.6× Block Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while Block Inc pays none. Which is the better fit depends on your goals.
| MRK | XYZ | |
|---|---|---|
Market Cap | $366.28B | $48.12B |
Sector | Health | Technology |
52-Week High | $156.43 | $84.85 |
52-Week Low | $77.60 | $49.04 |
Enterprise Value | $413.04B | $43.03B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
XYZ stock trades at $80.10, down 3.21% with a bearish technical signal. The company shows mixed fundamentals with strong revenue growth to $24.19B in 2025 but declining net income margins to 1.43%. Recent developments include expanding Cash App credit score access and applying for a national trust bank charter. Analyst consensus remains strongly bullish with 76% buy ratings and a $100.20 price target.
XYZ faces execution risks amid high P/E valuation of 143, though strategic initiatives in financial services provide growth catalysts. The stock offers 25% upside to consensus target but requires monitoring of profitability trends and regulatory approval for banking expansion.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Block Inc
Founded in 2009, Block provides payment acquiring services to merchants, along with related services. The company also launched Cash App, a person-to-person payment network. Block has operations in Canada, Japan, Australia, and the United Kingdom
Read more on XYZ →
